Kidney stenting lowers blood pressure in patients with severe hypertension

August 30, 2012

Patients with uncontrolled renovascular hypertension saw a significant improvement in their blood pressure with renal artery stent deployment. The multicenter HERCULES trial, evaluating the safety and effectiveness of the RX Herculink Elite Stent, found that patients with higher blood pressure levels at baseline had the most dramatic reduction in blood pressure following intervention. Trial details appear in Catheterization and Cardiovascular Interventions, a journal published by Wiley on behalf of the Society for Cardiovascular Angiography and Interventions (SCAI).

Narrowing of the arteries to the kidney—known as stenosis (RAS)—is mainly caused by the build-up of fat and cholesterol (atherosclerosis) along the . The plaque build-up can cause high blood pressure and . While kidney artery stenting is considered a safe procedure, the efficacy of the procedure for and preventing injury that leads to end-stage renal disease remains unclear, particularly when compared to medicines alone.

"Findings from the HERCULES trial expand scientific evidence of renal artery stenting in treating patients with who do not respond to standard therapy," explains Michael R. Jaff, DO, FSCAI, from the Vascular Center at Massachusetts General Hospital in Boston. "As part of the trial we also explored the predictive value of the brain natriuretic peptide (BNP) test prior to performing the stent procedure." The BNP test is used to diagnose and researchers sought to understand if BNP could predict clinical success, which is valuable information for interventionists prior to performing invasive procedures.

For the HERCULES trial researchers enrolled 202 patients with 241 total lesions and 78 bilateral lesions between August 2007 and October 2009. Patients had a history of and active or recently discontinued tobacco use. The majority of participants were Caucasian, mean age was 72 years, and 62% of patients were female. BNP testing was performed before and after stenting with the RX Herculink Elite Renal Stent System by Abbott Vascular.

At the start of the trial the mean systolic blood pressure of the trial group was 162 mm Hg and nearly 70% of patients were taking three or more medications to control hypertension. Success rates for the trial device, procedure and clinical outcomes were 96%, 99%, and 98%, respectively. Researchers reported that freedom from major adverse events (death, kidney removal, or embolism causing renal injury) was 95%.

Further results show that at the nine-month follow-up the restenosis rate was 11% and the mean systolic blood pressure for participants was 145 mm Hg post-stenting with no change in medications. Researchers found no association between a reduction in blood pressure following stenting and elevated BNP pre-procedure, or a decrease in BNP levels following successful stenting. While there was a significant decrease in BNP following stenting, the BNP level prior to the procedure was not reliable in predicting blood pressure response.

"The HERCULES trial demonstrates that renal artery stent revascularization significantly lowers systolic blood pressure in patients with severe hypertension," concludes Dr. Jaff. "Those patients with the highest blood pressure rates at baseline had the greatest magnitude of lowering." The authors point out that because the majority of trial participants were Caucasian the findings may not be applicable to other racial groups.

In a related video, Dr. Jaff discusses specifics of his research with Steven R. Bailey, MD, FSCAI, Editor-in-Chief of Catheterization and Cardiovascular Interventions. "The research by Dr. Jaff and colleagues is an important contribution to the evidence supporting stenting as an effective intervention for with renovascular disease," said Dr. Bailey.

Explore further: Renal denervation achieves significant and sustained blood pressure reduction

More information: "Significant Reduction in Systolic Blood Pressure Following Renal Artery Stenting in Patients with Uncontrolled Hypertension: Results from the HERCULES Trial." Michael R. Jaff, Mark Bates, Timothy Sullivan, Jeffrey Popma, Xingyu Gao, Margo Zaugg and Patrick Verta, on behalf of the HERCULES Investigators. Catheterization and Cardiovascular Interventions; Published Online: June 27, 2012 (DOI: 10.1002/ccd.24449); Print Issue Date: September, 2012.

Related Stories

Renal denervation achieves significant and sustained blood pressure reduction

August 27, 2012
Renal denervation leads to significant and sustained blood pressure reduction for up to 18 months in patients with treatment resistant hypertension, according to research presented at ESC Congress 2012. The new clinical data ...

Canada's first renal denervation procedure to reduce high blood pressure performed today

January 17, 2012
Doctors at the Peter Munk Cardiac Centre today performed a minimally invasive surgical procedure to treat high blood pressure, called renal denervation, for the first time in Canada. The procedure can significantly reduce ...

Study tests new therapy for treatment-resistant hypertension

June 28, 2012
(Medical Xpress) -- Treatment-resistant hypertension affects nearly 6 million Americans and another 94 million people worldwide and is associated with increased cardiovascular risk, including stroke and heart attack, as well ...

Simple procedure lowers blood pressure in kidney disease patients

May 17, 2012
Disrupting certain nerves in the kidneys can safely and effectively lower blood pressure in patients with chronic kidney disease (CKD) and hypertension, according to a study appearing in an upcoming issue of the Journal of ...

Recommended for you

Research suggests new pathways for hyperaldosteronism

December 7, 2017
A new study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP), in collaboration with researchers at Eunice Kennedy Shriver National Institute of Child Health and Human Development, part of the ...

One-dose gene therapy produces clotting factor, safely stops bleeding in hemophilia B patients

December 6, 2017
A team of gene therapy researchers has reported positive results in a phase 1/2 clinical trial for the inherited bleeding disorder hemophilia B. A single intravenous infusion of a novel bioengineered gene therapy treatment ...

Clot-busting drugs not recommended for most patients with blood clots

December 6, 2017
Not all patients with blood clots in their legs - a condition known as deep vein thrombosis - need to receive powerful but risky clot-busting drugs, according to results of a large-scale, multicenter clinical trial.

Mitochondrial protein in cardiac muscle cells linked to heart failure, study finds

December 5, 2017
Reducing a protein found in the mitochondria of cardiac muscle cells initiates cardiac dysfunction and heart failure, a finding that could provide insight for new treatments for cardiovascular diseases, a study led by Georgia ...

Blood pressure declines 14 to 18 years before death

December 4, 2017
Blood pressure in the elderly gradually begins to decrease about 14 or so years before death, according to a new study published today in the JAMA Internal Medicine.

Study links common male medical condition and vascular disease

December 1, 2017
Men who suffer symptoms from varicoceles, enlarged veins in the scrotum, are more likely to develop vascular disease and metabolic disease, such as diabetes, according to a study by Stanford University School of Medicine ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.